Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis
Wouter J. Plattel, Aurore Bergamasco, Fabrizio Trinchese, François Gavini, Nawal Bent‐Ennakhil, Athanasios Zomas, Genaro Castillon, T. Arredondo-Bisonó, Tiffany Cristarella, Yola Moride, Bastian von Tresckow
Abstract
= 64.8%), respectively. Regarding survival, 1-year, 2-year, and 5-year PFS ranged from 52.1% to 63.2%, 45.2% to 56.2%, and 31.9% to 33.0%, respectively. OS rates were 68.2-82.7%, 58.0-81.9%, and 58.0-62.0%, respectively. Most common adverse events were hematological toxicities (neutropenia: 13.3-23%, anemia: 8.8-39.0%, and thrombocytopenia: 4-4.6%), and grade ≥3 peripheral neuropathy (3.3-7.3%). This study supports the effectiveness and safety of BV in R/R cHL patients in the real-world setting.
Topics & Concepts
Brentuximab vedotinMedicineInternal medicineNeutropeniaAdverse effectConfidence intervalOncologyMeta-analysisAnemiaLymphomaObservational studyGastroenterologyHodgkin lymphomaChemotherapyLymphoma Diagnosis and TreatmentViral-associated cancers and disordersCNS Lymphoma Diagnosis and Treatment